Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in previously ...
Acalabrutinib, made by the drug company AstraZeneca and marketed under the brand name Calquence, works by blocking an enzyme called Bruton’s tyrosine kinase (BTK), which helps cancerous B cells ...
who are ineligible for autologous hematopoietic stem cell transplantation (HSCT), according to a news release from AstraZeneca. Importantly, Calquence is now the first and only Bruton tyrosine kinase ...
5d
Hosted on MSNAstraZeneca Rises Almost 9% in a Month: How to Play the StockAstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...
AstraZeneca Q4 revenue rose 18% to $14.89 ... Tagrisso sales were up 20% to $1.70 billion (21% at CER), Calquence sales increased 20% to $808 million, Lynparza sales increased 46% (+47%) to ...
AstraZeneca PLC has a 12-month low of $62. ... The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta ...
AstraZeneca’s other drugs, Fasenra, Calquence, Breztri and newer products, asthma drug Tezspire, breast cancer drug Truqap and lupus drug Saphnelo (anifrolumab) are likely to have contributed to ...
AstraZeneca Price Performance AZN opened at $74.56 on Friday. The company has a market capitalization of $231.22 billion, a P/E ratio of 32.99, a PEG ratio of 1.44 and a beta of 0.46. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results